Replies to post #217286 on Biotech Values

[DewDiligence]

BMY-NKTR 8-K filing has more details than PR:

https://www.sec.gov/Archives/edgar/data/906709/000119312518044320/d499642d8k.htm

[dewophile]

thx ghmm
it sounds like this locks in opdivo for 214 for at minimum 3 years which is where a lot of the value of the collaboration lies from BMY's standpoint. The fact NKTR retains control of pricing is also important since BMY's motive would otherwise be to maintain opdivo pricing in combinations at the expense of 214.
an outright purchase of NKTR by BMY would have been more damaging to the competition since it would lock out other PD-1s indefinitely, but a 3 year head start is still great for brisol
this is a very interestingly crafted deal balancing out exclusivity, up front risk, and control over the asset - i think a good deal for both parties

[biocqr]

NKTR > more 214/262 preclinical combo data tomorrow...including adoptive cell therapy...

>>>On the call Howard Robin mentioned doing something with CAR-T but it wasn't clear if that is just hype or something that may be in the nearer term. <<<

Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2018

Abstract 3566/Poster 4: "Enhanced expansion and tumor targeting of adoptively transferred T cells with NKTR-214", Parisi, G., et al.
Session: Adoptive Cell Therapy 3
Session Date and Time: Tuesday, April 17, 2018, 8:00 a.m. - 12:00 p.m. Central Time
Location: McCormick Place South, Exhibit Hall A, Poster Section 24

NKTR-214 + ACT was well tolerated and provides a robust anti-tumor response in the aggressive B16F10 melanoma tumor model.
Treatment with NKTR-214 + ACT mobilizes T cells into the tumor where they durably persist without expanding T cells in the periphery.
The robust and long-lasting effect of NKTR-214 supports its potential use in combination with cell-based therapeutics.

[DewDiligence]

NKTR, PFE ink clinical-trial collaboration for NKTR-214 with PFE compounds:

https://finance.yahoo.com/news/clinical-oncology-collaboration-between-nektar-133000524.html

Under the new collaboration, Pfizer will initiate a Phase 1b/2 clinical trial to evaluate the anti-cancer activity of the combined agents, avelumab, talazoparib and NKTR-214 and separately avelumab, enzalutamide and NKTR-214. Nektar, Pfizer and their respective partners will each maintain global commercial rights to their respective medicines.

The indications to be tested include CRPC and SCCHN.

No cash is changing hands, apparently.